Associate Professor, Division of Endocrinology and Metabolism, Department of Medicine, and Institute of Health Policy, Management and Evaluation, University of Toronto
Goal Groups/Integration Themes:
Lead - Clinical Trials and New Therapies
Centered on type 1 diabetes and using longitudinal cohort methods as well as clinical trials, his research work has focused on 1) Early biomarkers of diabetes complications and biomarkers of progression to advanced disease, and 2) Interventions for prevention of complications, including artificial pancreas technologies and disease-modifying adjunctive-to-insulin pharmacotherapies. Principal findings include “early progressive renal decline” which permitted identification of novel factors now subject to a large-scale nephropathy clinical trial, and the development of In-vivo Corneal Confocal Microscopy as an early small fibre biomarker for neuropathy for which he leads an NIH-funded international consortium. He leads a phase 3 trial of Sodium Glucose-Linked Transporter-2 inhibition in type 1 diabetes, and his first project in the Diabetes Action Canada portfolio combines such adjunctive therapy with artificial pancreas technology as a strategy to maximally impact glycemic control in type 1 diabetes.
Home Page/Departmental Page: